Back to News
Market Impact: 0.4
Roche's Lunsumio Shows Improved OS And PFS In Comparative Study For Follicular Lymphoma
Source: Nasdaq
Healthcare & BiotechProduct Launches
Roche announced that its Phase 3 CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The positive late-stage result supports the potential expansion of Roche's lymphoma treatment portfolio, although the article provides no efficacy magnitude, safety data, or regulatory timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Citizens reiterates Ondas Holdings stock rating on IonStrike updates
- Wells Fargo raises Regeneron stock price target to $925 on execution